Aspirin Effectively Reduces Cancer Recurrence After Radical Prostatectomy: Study

Also, the analysis of high-risk subgroups yielded even more strong data. Among patients with an International Society of Urological Pathology (ISUP) grade of 4 or higher, aspirin use was associated with a significantly lower recurrence rate. The hazard ratio (HR) for recurrence in the aspirin group was 0.44 (95% CI 0.22–0.88, PSM) and 0.45 (95% CI 0.23–0.90, MDM) which suggested nearly a 56% reduced risk of recurrence in these high-risk patients.

The study underlined the potential of aspirin as a supplementary therapy in improving cancer outcomes for patients undergoing RARP for the patients with more aggressive disease profiles. By inhibiting platelet activity, aspirin may reduce cancer progression and reduce the likelihood of residual tumor cells spreading after surgery.

The findings offer a valuable avenue for future research, as well as potential clinical implications for improving post-surgical care. Overall, this study represents a step forward in understanding how readily available medications like aspirin can complement advanced surgical treatments to improve patient outcomes in prostate cancer management.

Reference:

Suzuki, S., Negoro, H., Kubota, M., Sumiyoshi, T., Saito, R., Okuno, T., Segawa, T., Fukuzawa, S., Onishi, H., Hattahara, K., Nagahama, K., Sekine, Y., Kurahashi, R., Shimatani, K., Sawada, A., Akamatsu, S., Nishiyama, H., Goto, T., & Kobayashi, T. (2025). Impact of aspirin on biochemical recurrence of prostate cancer after robot assisted radical prostatectomy in a multicenter retrospective cohort study. Scientific Reports, 15(1), 2025. https://doi.org/10.1038/s41598-025-86521-x